RemeGen Co Ltd
HKEX:9995

Watchlist Manager
RemeGen Co Ltd Logo
RemeGen Co Ltd
HKEX:9995
Watchlist
Price: 63.95 HKD 1.19% Market Closed
Market Cap: 66.2B HKD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
-31%
Revenue
Forecast
+37%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
RemeGen Co Ltd

Wall Street analysts forecast RemeGen Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RemeGen Co Ltd is 37.97 HKD with a low forecast of 23.23 HKD and a high forecast of 49.81 HKD.

Lowest Forecast
Wall Street Target
23.23 HKD
64% Downside
Average Forecast
Wall Street Target
37.97 HKD
41% Downside
Highest Forecast
Wall Street Target
49.81 HKD
22% Downside
Lowest
Price Target
23.23 HKD
64% Downside
Average
Price Target
37.97 HKD
41% Downside
Highest
Price Target
49.81 HKD
22% Downside
RemeGen Co Ltd Competitors:
Price Targets
9926
Akeso Inc
11% Downside
4974
Takara Bio Inc
55% Upside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
9% Downside
87S
Roivant Sciences Ltd
59% Upside
9926
Akeso Inc
11% Downside
4974
Takara Bio Inc
55% Upside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
9% Downside
87S
Roivant Sciences Ltd
59% Upside
N
NXTC
NextCure Inc
38% Downside
BEAM
Beam Therapeutics Inc
113% Upside
P
214450
PharmaResearch Co Ltd
24% Downside
IONS
Ionis Pharmaceuticals Inc
37% Upside

Revenue
Forecast

Revenue Estimate
RemeGen Co Ltd

The compound annual growth rate of RemeGen Co Ltd's revenue for the next 3 years is 37%.

N/A
Past Growth
37%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
RemeGen Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
11%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
RemeGen Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RemeGen Co Ltd's stock price target?
Price Target
37.97 HKD

According to Wall Street analysts, the average 1-year price target for RemeGen Co Ltd is 37.97 HKD with a low forecast of 23.23 HKD and a high forecast of 49.81 HKD.

What is RemeGen Co Ltd's Revenue forecast?
Projected CAGR
37%

The compound annual growth rate of RemeGen Co Ltd's revenue for the next 3 years is 37%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 267,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.